Iclaprim D6

Iclaprim D6 is a deuterated form of Iclaprim, a novel diaminopyrimidine antibiotic that is used to treat serious bacterial infections. It is a potent inhibitor of bacterial dihydrofolate reductase, an enzyme that is essential for the synthesis of DNA, RNA, and proteins. Iclaprim D6 is used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The chemical formula of Iclaprim D6 is C14H8D6N7O2S2, and its molecular weight is 395.49 g/mol. It is a white to off-white crystalline powder that is soluble in water and organic solvents. The deuterated form of Iclaprim is used in pharmacokinetic studies to determine the metabolic fate of the drug in the body. The deuterium atoms in Iclaprim D6 are stable isotopes of hydrogen, which can be detected by mass spectrometry. The recommended dose of Iclaprim D6 is 0.8 mg/kg body weight, administered intravenously over 1 hour every 12 hours for 5-14 days, depending on the severity of the infection. The drug is metabolized in the liver and excreted in the urine, with a half-life of about 8 hours. Iclaprim D6 has a low potential for drug interactions, and its side effects are generally mild and transient, including nausea, vomiting, and diarrhea. In conclusion, Iclaprim D6 is a promising new antibiotic that offers a valuable option for the treatment of serious bacterial infections.